<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389870</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000510284</org_study_id>
    <secondary_id>CTRU-PICCOLO-MO-05-7289</secondary_id>
    <secondary_id>EUDRACT-2005-003492-20</secondary_id>
    <secondary_id>CTAAC-CTRU-PICCOLO-MO-05-7289</secondary_id>
    <secondary_id>AMGEN-CTRU-PICCOLO-MO-05-7289</secondary_id>
    <secondary_id>EU-20647</secondary_id>
    <nct_id>NCT00389870</nct_id>
  </id_info>
  <brief_title>Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil</brief_title>
  <official_title>A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan &amp; Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the
      drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
      kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of
      tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
      whether irinotecan is more effective when given with or without panitumumab or cyclosporine
      in treating colorectal cancer.

      PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works
      when given with or without panitumumab or cyclosporine in treating patients with advanced or
      metastatic colorectal cancer that did not respond to fluorouracil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy and toxicity of single-agent irinotecan hydrochloride (Ir) vs Ir
           with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal
           cancer.

        -  Compare the efficacy of single-agent Ir vs Ir with panitumumab (IrP) in these patients.

      Secondary

        -  Correlate the toxicity of Ir and/or IrC with genetic variability in the enzymes involved
           in irinotecan hydrochloride's disposition pathway.

        -  Compare IrC to Ir and its metabolites (SN38; SN38G), in terms of pharmacokinetic
           profile.

        -  Correlate the benefit of IrP with tumor expression of epidermal growth factor receptor
           (EGFR) or its known down-stream molecules as a predictive measure.

        -  Correlate IrP efficacy or toxicity (specifically the severity of skin rash) with somatic
           alterations in the EGFR gene and/or with germline variability in related genes.

      OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are
      stratified according to prior cetuximab (yes vs no). Patients are randomized to 1 of 3
      treatment arms.

        -  Arm I: Patients receive irinotecan hydrochloride IV over 30-90 minutes on day 1.

        -  Arm II: Patients receive irinotecan hydrochloride IV over 15-40 minutes on day 1 and
           oral cyclosporine three times a day on days 1-3.

        -  Arm III: Patients receive panitumumab IV over 30-90 minutes followed by irinotecan
           hydrochloride IV over 30-90 minutes on day 1. Single-agent panitumumab may be continued
           during breaks in chemotherapy treatment.

      In all arms, treatment repeats every 3 weeks for 4 courses in the absence of disease
      progression or unacceptable toxicity. Patients with responding or stable disease may continue
      treatment in the absence of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline and at 12 and 24 weeks.

      After completion of study treatment, patients are followed every 12 weeks for 1 year.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: A total of 1,269 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free from treatment failure at 12 weeks in patients treated with Ir vs IrC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in patients treated with Ir vs IrC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nurse-assessed toxicity (all-cause mortality, diarrhea ≥ grade 3 at 12 weeks) in patients treated with Ir vs IrC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free at 12 weeks in patients treated with Ir vs IrP and no prior cetuximab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nurse assessed toxicity (all-cause mortality) in patients treated with Ir vs IrP and no prior cetuximab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in patients treated with Ir vs IrP and prior cetuximab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response at 1 year in patients treated with Ir vs IrP and prior cetuximab</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1269</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>panitumumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of colorectal adenocarcinoma meeting 1 of the following criteria:

               -  Previous or current histologically confirmed primary adenocarcinoma of the colon
                  or rectum and clinical/radiological evidence of advanced or metastatic disease

               -  Histologically or cytologically confirmed metastatic adenocarcinoma with clinical
                  or radiological evidence of colorectal primary tumor

          -  Unidimensionally measurable disease

          -  Disease progression during or after prior fluorouracil with or without oxaliplatin
             therapy and/or with or without bevacizumab

               -  Adjuvant therapy and/or prior therapy for advanced disease allowed

          -  No clinical or radiological evidence of pleural effusion or ascites causing ≥ grade 2
             dyspnea

          -  No clinical or radiological evidence of biliary obstruction

          -  No known CNS metastases or carcinomatous meningitis

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  Hemoglobin &gt; 10.0 g/dL

          -  WBC &gt; 3,000/mm³

          -  Platelet count &gt; 100,000/mm³

          -  Glomerular filtration rate &gt; 50 mL/min OR EDTA clearance &gt; 60 mL/min

          -  Bilirubin &lt; 1.46 mg/dL

          -  Alkaline phosphatase ≤ 5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  No history of Gilbert's syndrome

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  Capable of completing quality of life questionnaires

          -  No prior anaphylactic allergic reaction to cetuximab

          -  No other prior or concurrent cancer (excluding nonmelanomatous skin cancer)

          -  No unresolved bowel obstruction, uncontrolled gastrointestinal infection, chronic
             enteropathy (e.g., Crohn's disease or ulcerative colitis), or chronic diarrhea (≥ 4
             stools per day) of any cause

          -  No recent history of seizures

          -  No clinical or radiological evidence of interstitial pneumonitis or pulmonary
             fibrosis,

          -  Capable of reliable oral self-medication

          -  No other condition that would make the patient unsuitable for participation in this
             study

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No major thoracic or abdominal surgery within the past 4 weeks

          -  No systemic anticancer therapy within the past 3 weeks

          -  No prior irinotecan hydrochloride

          -  No grapefruit juice within 3 days before and after each chemotherapy treatment

          -  No experimental drug therapy or antibody therapy, other than cetuximab, within the
             past 6 weeks

          -  No systemic chemotherapy and/or cetuximab within the past 3 weeks

          -  No antifungals or antibiotics within the past 5 days

          -  No ongoing requirement for cyclosporine or any other medication including, but not
             limited to, the following:

               -  Ketoconazole, fluconazole, itraconazole

               -  Erythromycin, clarithromycin, norfloxacin

               -  Diltiazem hydrochloride, verapamil, amiodarone hydrochloride

               -  Fluvoxamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew T. Seymour, MA, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cookridge Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hickish, MD</last_name>
      <phone>44-120-230-3626</phone>
      <email>tamas.hickish@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Webb, MD</last_name>
      <phone>44-12-7369-6955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen J. Falk, MD</last_name>
      <phone>44-117-928-2416</phone>
      <email>stephen.falk@ubht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles B. Wilson, MD</last_name>
      <phone>44-1223-217-110</phone>
      <email>charles.wilson@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Oncology Centre at Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>England</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Benstead, MD</last_name>
      <phone>44-845-422-2222</phone>
      <email>kim.benstead@egnhst.org.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>England</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona McKinna, MD</last_name>
      <phone>44-132-341-7400</phone>
      <email>fiona.mckinna@bsuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary W. Middleton</last_name>
      <phone>44-148-357-1122</phone>
      <email>gmiddleton@royalsurrey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield, West Yorks</city>
        <state>England</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Dent</last_name>
      <phone>44-1484-342-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <state>England</state>
        <zip>PE18 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Tee Tan, MD</last_name>
      <phone>44-1480-416-416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Airedale General Hospital</name>
      <address>
        <city>Keighley</city>
        <state>England</state>
        <zip>BD20 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Michael Crawford, MD</last_name>
      <phone>44-1535-652-511</phone>
      <email>michael.crawford@anhst.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew T. Seymour, MA, MD, FRCP</last_name>
      <phone>44-113-267-3411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <phone>44-151-706-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Mayer, MD</last_name>
      <phone>44-207-794-0500</phone>
      <email>a.mayer@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital - Woolwich</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Maisey</last_name>
      <phone>44-208-836-6000</phone>
      <email>nick.maisey@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cleator, MD, PhD</last_name>
      <phone>44-207-886-6666</phone>
      <email>s.cleator@imperial.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hill, MD</last_name>
      <phone>44-1622-729-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Myint, MD, FRCP(Edin), DMRT, FFRCS, F</last_name>
      <phone>44-151-334-1155</phone>
      <email>sun.myint@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N. Wadd, MD</last_name>
      <phone>44-1642-850-850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Glynne-Jones, MD</last_name>
      <phone>44-192-382-6111</phone>
      <email>robglynnejones@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peterborough Hospitals Trust</name>
      <address>
        <city>Peterborough</city>
        <state>England</state>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen E. McAdam, MD</last_name>
      <phone>44-173-387-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hickish, MD</last_name>
      <phone>44-120-266-5511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portsmouth Oncology Centre at Saint Mary's Hospital</name>
      <address>
        <city>Portsmouth Hants</city>
        <state>England</state>
        <zip>PO3 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann O'Callaghan, MD</last_name>
      <phone>44-23-9228-6000 ext. 2361</phone>
      <email>ann.o'callaghan@porthosp.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Wadsley</last_name>
      <phone>44-114-226-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <state>England</state>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Azzabi, MD</last_name>
      <phone>44-191-202-4178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Chau, MD</last_name>
      <phone>44-208-661-3582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <state>England</state>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Blesing</last_name>
      <phone>44-1793-604-020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Webb, MD</last_name>
      <phone>44-1903-205-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>England</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen J. Falk, MD</last_name>
      <phone>44-193-547-5122</phone>
      <email>stephen.falk@swest.uhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Dawson</last_name>
      <phone>44-131-537-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <state>Wales</state>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bale</last_name>
      <phone>44-124-838-4384</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Maughan, MD</last_name>
      <phone>44-29-2061-5888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Gollins, MD</last_name>
      <phone>44-1745-583-910</phone>
      <email>simon.gollins@cd-tr.wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wagstaff, MD, MB, ChB, FRCP</last_name>
      <phone>44-179-220-2666</phone>
      <email>profwagstaff@netscape.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

